Medical Devices Startups

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.

9 investors

Forescout provides cyber-physical systems security and network access control solutions for IoT, OT, and medical device environments. The company serves enterprises managing IoT and industrial control system security risks.

9 investors

Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.

9 investors

Getlabs provides at-home lab sample collection, sending phlebotomists to patients to draw blood and collect samples for lab tests ordered by their providers. Lab results are shared directly with the patient and the ordering provider, with support for connecting results to the Apple Health app.

9 investors

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas. The company focuses on creating transformative treatments for patients in high-need therapeutic categories.

9 investors

HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients. The company markets its technology to healthcare providers internationally.

9 investors

Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.

9 investors

Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications. The company runs an Investigator-Initiated Studies grants program to support independent research on diagnostic testing outcomes, health economics, and fundamental science related to its sequencing technology.

9 investors

Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.

9 investors

Luminate develops medical device technology to address chemotherapy side effects, particularly hair loss and peripheral neuropathy, for oncology patients and healthcare providers. The company is advancing clinical-stage devices while supporting cancer patients, clinicians, and health systems.

9 investors

Magnetic Particle Imaging (MPI) is an imaging technology that detects iron oxide nanoparticle tracers using time-varying magnetic fields to create medical images with high contrast and sensitivity. The company develops this emerging imaging modality for medical imaging and in vivo translational research applications.

9 investors

Mediartx develops novel therapies for patients with fibrotic diseases.

9 investors

Medisafe is a medication engagement platform that helps pharmaceutical companies connect with patients beyond the prescription and improve treatment adherence. The platform uses personalized, intelligent engagement to support patients with complex therapies across multiple therapeutic areas.

9 investors

MEDZOOMER operates an on-demand prescription delivery platform that connects patients with pharmacies to enable remote access to medications. The service is designed for pharmacies, delivery partners, and patients seeking secure, compliant prescription fulfillment and delivery.

9 investors

Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain. The system consists of an implanted microstimulator, a separate electrode array, and an externally worn, battery-free therapy disc, offered as a drug-free treatment option to patients through their doctors.

9 investors

Nicoya provides digital biosensing instruments for biophysical characterization, enabling scientists to study molecular behavior and protein interactions in drug discovery and structural analysis. The company serves research institutions and biotech discovery teams with label-free binding kinetics, thermal shift screening, and hydrogen-deuterium exchange technologies.

9 investors

OrganOx develops the metra platform, a device that extends organ preservation time for liver transplants by maintaining continuous perfusion with oxygenated blood-based solutions, enabling surgeons to better assess organ viability and make more informed transplant decisions.

9 investors

PhotoniCare develops OtoSight, an FDA-cleared optical coherence tomography device for non-invasive assessment and monitoring of middle ear infections in healthcare facilities. The technology is designed for physicians treating ear-related conditions and offers improved accuracy over traditional otoscope methods.

9 investors

Precision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts. The company works with hospital clinical partners on implanted studies and positions its technology as removable and upgradable without damaging the brain.

9 investors

QD Laser develops, manufactures, and sells high-efficiency semiconductor lasers for telecommunications and industrial use, as well as visual-information devices. The company is based in Yokohama, Japan and is listed on the Tokyo Stock Exchange Growth Market.

9 investors

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.

9 investors

Qvin develops the Q-Pad, an FDA-cleared diagnostic menstrual pad that collects menstrual blood samples for non-invasive health monitoring and disease diagnosis. The company uses biomarker analysis from menstrual fluid to serve healthcare organizations and diagnostic platforms in women's health diagnostics.

9 investors

Rubedo Life Sciences develops therapeutics targeting aging by eliminating senescent cells to extend human healthspan. The company applies artificial intelligence and chemistry to drug discovery in the longevity and regenerative medicine space.

9 investors

Samphire Neuro develops brain-based neurotechnology medical devices to treat chronic pain and mood conditions in women, targeting PMDD, dysmenorrhea, perimenopause, chronic migraines, and endometriosis. Its flagship non-invasive neurostimulation headband has clearance in the UK and EU and is expanding into the United States.

9 investors